Recruiting Phase 3 NCT06643130

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Trial Parameters

Condition Hypertension

Sponsor JW Pharmaceutical

Study Type INTERVENTIONAL

Phase Phase 3

Enrollment 162

Sex ALL

Min Age 19 Years

Max Age N/A

Start Date 2024-12-02

Completion 2026-04

All Conditions

Hypertension Dyslipidemia

Interventions

JW0104+C2402JW0104+C2403C2402

Brief Summary

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Eligibility Criteria

Inclusion Criteria: * Patients with hypertension and dyslipidemia Exclusion Criteria: * The subject not meet the specified msBP and LDL-C level

Related Trials

NCT04832009

Reversing Glucose and Lipid-mediated Vascular Dysfunction

View Trial →

NCT06322056

Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in A

View Trial →

NCT05411029

Study of Disrupted Sleep in Somali Americans

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE HYPERTENSION TRIALS